Tiltan Pharma Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Tiltan Pharma General Information

Description

Developer of a proprietary anti-angiogenic and immune-modulatory platform designed to offer innovative cancer therapies. The company's platform develops TL-118, is an oral drug combination with anti-cancer, antiangiogenic and immune-modulatory properties, enabling healthcare institutions to avail drugs to treat cancer effectively.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 2.4 Hi tech Village, Edmond Safra campus
  • Givat Ram P.O. Box 39026
  • Jerusalem 91390
  • Israel
+972
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Vertical(s)
Corporate Office
  • 2.4 Hi tech Village, Edmond Safra campus
  • Givat Ram P.O. Box 39026
  • Jerusalem 91390
  • Israel
+972

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tiltan Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Sep-2019 Completed Out of Business
3. Later Stage VC 05-Feb-2014 Completed Generating Revenue
2. Grant 01-Feb-2009 $1.2M Completed Startup
1. Early Stage VC 01-Jan-2007 Completed Startup
To view Tiltan Pharma’s complete valuation and funding history, request access »

Tiltan Pharma Patents

Tiltan Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2018069924-A1 Non-cytotoxic combination therapies and uses thereof in the treatment of cancer Inactive 10-Oct-2016
WO-2016166761-A1 Combination therapies and uses thereof in the treatment of cancer Inactive 14-Apr-2015
AU-2013208649-A1 Combination therapy for the treatment of cancer Active 09-Jan-2012
AU-2013208649-B2 Combination therapy for the treatment of cancer Inactive 09-Jan-2012
CA-2860473-A1 Combination therapy for the treatment of cancer Inactive 09-Jan-2012 A61K31/7068
To view Tiltan Pharma’s complete patent history, request access »

Tiltan Pharma FAQs

  • When was Tiltan Pharma founded?

    Tiltan Pharma was founded in 2006.

  • Where is Tiltan Pharma headquartered?

    Tiltan Pharma is headquartered in Jerusalem, Israel.

  • What industry is Tiltan Pharma in?

    Tiltan Pharma’s primary industry is Biotechnology.

  • Is Tiltan Pharma a private or public company?

    Tiltan Pharma is a Private company.

  • What is Tiltan Pharma’s current revenue?

    The current revenue for Tiltan Pharma is .

  • How much funding has Tiltan Pharma raised over time?

    Tiltan Pharma has raised $1.5M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process